Company: INMB
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003354
Chunk: 239

Company: Inmune Bio, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1A
Chunk 239
---
U 2023-07,
Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”), which enhances
the disclosures required for operating segments in the Company’s annual and interim consolidated financial statements, including those
companies with a single operating segment. ASU 2023-07 is effective retrospectively for fiscal years beginning after December 15, 2023
and for interim periods within fiscal years beginning after December 15, 2024. The Company adopted ASU 2023-07 for the year ended December
31, 2024. See Note 13 for segment disclosures.

In December 2023, the FASB issued ASU 2023-09, Income
Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”). The guidance in ASU 2023-09 improves the
transparency of income tax disclosures by greater disaggregation of information in the rate reconciliation and income taxes paid disaggregated
by jurisdiction. The standard is effective for public companies for fiscal years beginning after December 15, 2024, with early adoption
permitted. The Company is currently evaluating the impact that the adoption of ASU 2023-09 may have on its consolidated financial statements. 

In November 2024, the FASB issued ASU 2024-03,
Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income
Statement Expenses (“ASU 2024-03”). ASU 2024-03 requires additional disclosure of specific types of expenses included
in the expense captions presented on the face of the income statement as well as disclosures about selling expenses. ASU 2024-03 is effective
for fiscal years beginning after December 15, 2026, and interim periods beginning after December 15, 2027, with early adoption permitted.
ASU 2024-03 may be applied prospectively with the option for retrospective application for all prior periods presented. The Company is
currently evaluating the impact of adopting this guidance on the Company’s current financial position, results of operations or financial
statement disclosures.

F-10

Subsequent Events

The Company has evaluated all transactions through
the financial statement issuance date for subsequent disclosure consideration.

NOTE 4 – RESEARCH AND DEVELOPMENT
ACTIVITY

According to UK tax law, the Company is allowed
an